Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer. 2017

Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
Laboratory of Virology, College of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul 06974, South Korea.

Serum autoantibodies against tumor-associated antigens (TAAs) have received much attention as potential biomarkers for early detection of cancers, since they can be detected in the early stages of cancers. Autoantibodies against Cancer Antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), Cancer Antigen 19-9 (CA19-9), c-Myc, p53, heat shock protein (Hsp)27 and Hsp70 have been suggested as potential markers for detecting several types of cancer. In the present study, the seven types of antibody listed above were evaluated for detecting cervical lesions. Enzyme-linked immunosorbent assays (ELISAs) were used to measure IgG levels of the autoantibodies in women with normal cytology, cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III and cervical cancer. The increases of anti-CA15-3 and anti-CEA IgG in cervical cancer were more pronounced than the increases of the other markers, and the level of anti-CA19-9 IgG in CIN III stage was higher than in normal CIN I, CIN II or cervical cancer. A combination of ELISAs detecting anti-CA15-3, anti-CEA and anti-CA19-9 IgGs was found to reliably discriminate CINs from normal and to strongly differentiate cancer from normal (90.3% of sensitivity and 82.1% of specificity). We suggest that the combination of three ELISA may be useful for detecting cervical lesions.

UI MeSH Term Description Entries

Related Publications

Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
October 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
April 2015, Journal of proteomics,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
February 2021, Translational oncology,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
March 2010, Current molecular medicine,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
May 2014, Cancer letters,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
April 2011, Autoimmunity reviews,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
March 2017, Cancer science,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
December 2020, Clinical and translational gastroenterology,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
November 2021, Journal of clinical laboratory analysis,
Yingji Jin, and Seung Cheol Kim, and Hyoung Jin Kim, and Woong Ju, and Yun Hwan Kim, and Hong-Jin Kim
May 2013, Experimental hematology & oncology,
Copied contents to your clipboard!